Asset Management One Co. Ltd. Sells 312 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Asset Management One Co. Ltd. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 141,561 shares of the pharmaceutical company’s stock after selling 312 shares during the period. Asset Management One Co. Ltd.’s holdings in Vertex Pharmaceuticals were worth $63,023,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in VRTX. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals in the first quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares in the last quarter. Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals in the first quarter valued at $32,000. American National Bank & Trust lifted its position in Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after buying an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $46,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX opened at $422.63 on Friday. The stock has a 50-day moving average price of $398.38 and a 200-day moving average price of $435.23. The firm has a market cap of $108.36 billion, a PE ratio of 30.21 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 25th. Royal Bank Of Canada lowered their price target on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 5th. BMO Capital Markets set a $530.00 price target on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Stifel Nicolaus lowered their price target on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research report on Tuesday, August 5th. Finally, Evercore ISI lowered their price target on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $494.38.

Insider Activity

In related news, Director Bruce I. Sachs purchased 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.